The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first line treatment.
 
Kazuaki Harada
Speakers' Bureau - Bayer; Bristol Myers Squibb; DAIICHI SANKYO COMPANY, LIMITED; Lilly; Merck Serono; MSD Oncology; Nippon Kayaku; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical
 
Shintaro Nakano
No Relationships to Disclose
 
Yasuyuki Kawamoto
Honoraria - AstraZeneca; Incyte; Lilly Japan; Merck; Nihon Servier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Taiho Pharmaceutical
Research Funding - Japan Agency for Medical Research and Development; Takeda
 
Kentaro Sawada
No Relationships to Disclose
 
Takuto Miyagishima
No Relationships to Disclose
 
Susumu Sogabe
No Relationships to Disclose
 
Yoshimitsu Kobayashi
No Relationships to Disclose
 
Ken Ito
No Relationships to Disclose
 
Atsushi Sato
No Relationships to Disclose
 
Chen Yu
No Relationships to Disclose
 
Masayoshi Dazai
No Relationships to Disclose
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Isao Yokota
Speakers' Bureau - AstraZeneca; Chugai Pharma
Research Funding - Nihon Medi-Physics
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); DAIICHI SANKYO CO., LTD.; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; MSD K.K.; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Yakult Honsha